Astellas and Seattle Genetics (now Seagen) formed a global collaboration to develop enfortumab vedotin (Padcev), a Nectin-4 targeting ADC for urothelial cancer. The multi-year collaboration involved shared development costs and co-commercialization. Padcev was approved by FDA in 2019 and expanded to first-line use with Keytruda in 2023, generating >$3.4B in sales by 2024. Pfizer acquired Seagen in 2023 inheriting co-commercialization rights.